P De Koning Harry
Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK.
Trop Med Infect Dis. 2020 Jan 19;5(1):14. doi: 10.3390/tropicalmed5010014.
With the incidence of sleeping sickness in decline and genuine progress being made towards the WHO goal of eliminating sleeping sickness as a major public health concern, this is a good moment to evaluate the drugs that 'got the job done': their development, their limitations and the resistance that the parasites developed against them. This retrospective looks back on the remarkable story of chemotherapy against trypanosomiasis, a story that goes back to the very origins and conception of chemotherapy in the first years of the 20 century and is still not finished today.
随着昏睡病发病率的下降，以及在实现世界卫生组织将昏睡病作为重大公共卫生问题予以消除的目标方面取得了切实进展，现在是评估那些“完成了任务”的药物的好时机：它们的研发、局限性以及寄生虫对它们产生的耐药性。这一回顾追溯了抗锥虫病化疗的非凡历程，这个故事可以追溯到20世纪初化疗的起源和概念，至今仍未结束。
